Logo image of NBP

NOVABRIDGE BIOSCIENCES (NBP) Stock Fundamental Analysis

USA - NASDAQ:NBP - US44975P1030 - ADR

4.15 USD
-0.02 (-0.48%)
Last: 11/14/2025, 8:08:35 PM
4.13 USD
-0.02 (-0.48%)
After Hours: 11/14/2025, 8:08:35 PM
Fundamental Rating

3

NBP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NBP as it has an excellent financial health rating, but there are worries on the profitability. NBP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NBP had negative earnings in the past year.
NBP had negative earnings in 4 of the past 5 years.
In the past 5 years NBP reported 4 times negative operating cash flow.
NBP Yearly Net Income VS EBIT VS OCF VS FCFNBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

NBP has a better Return On Assets (-18.22%) than 77.21% of its industry peers.
NBP has a Return On Equity of -19.14%. This is amongst the best in the industry. NBP outperforms 84.75% of its industry peers.
Industry RankSector Rank
ROA -18.22%
ROE -19.14%
ROIC N/A
ROA(3y)-42.75%
ROA(5y)-32.49%
ROE(3y)-60.9%
ROE(5y)-45.09%
ROIC(3y)N/A
ROIC(5y)N/A
NBP Yearly ROA, ROE, ROICNBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

NBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBP Yearly Profit, Operating, Gross MarginsNBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

More info and screens

8

2. Health

2.1 Basic Checks

NBP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NBP has more shares outstanding
NBP has more shares outstanding than it did 5 years ago.
There is no outstanding debt for NBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NBP Yearly Shares OutstandingNBP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NBP Yearly Total Debt VS Total AssetsNBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

An Altman-Z score of 20.47 indicates that NBP is not in any danger for bankruptcy at the moment.
NBP has a Altman-Z score of 20.47. This is amongst the best in the industry. NBP outperforms 90.40% of its industry peers.
NBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.47
ROIC/WACCN/A
WACC8.66%
NBP Yearly LT Debt VS Equity VS FCFNBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

A Current Ratio of 22.86 indicates that NBP has no problem at all paying its short term obligations.
NBP's Current ratio of 22.86 is amongst the best of the industry. NBP outperforms 96.05% of its industry peers.
A Quick Ratio of 22.86 indicates that NBP has no problem at all paying its short term obligations.
NBP's Quick ratio of 22.86 is amongst the best of the industry. NBP outperforms 96.05% of its industry peers.
Industry RankSector Rank
Current Ratio 22.86
Quick Ratio 22.86
NBP Yearly Current Assets VS Current LiabilitesNBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 89.81% over the past year.
Looking at the last year, NBP shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)89.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.65%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NBP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.12% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.9%
EPS Next 2Y26.6%
EPS Next 3Y15.11%
EPS Next 5Y13.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NBP Yearly Revenue VS EstimatesNBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2028 2029 2030 2031 2032 0 500M 1B 1.5B
NBP Yearly EPS VS EstimatesNBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NBP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBP Price Earnings VS Forward Price EarningsNBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBP Per share dataNBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as NBP's earnings are expected to grow with 15.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.6%
EPS Next 3Y15.11%

More info and screens

0

5. Dividend

5.1 Amount

NBP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVABRIDGE BIOSCIENCES

NASDAQ:NBP (11/14/2025, 8:08:35 PM)

After market: 4.13 -0.02 (-0.48%)

4.15

-0.02 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-20 2025-08-20/bmo
Earnings (Next)04-01 2026-04-01/amc
Inst Owners9.62%
Inst Owner ChangeN/A
Ins Owners0.56%
Ins Owner ChangeN/A
Market Cap478.35M
Revenue(TTM)N/A
Net Income(TTM)-37.71M
Analysts86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.53%
Min EPS beat(2)-63.37%
Max EPS beat(2)54.3%
EPS beat(4)1
Avg EPS beat(4)-13.87%
Min EPS beat(4)-63.37%
Max EPS beat(4)54.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.43
P/tB 2.43
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS1.71
TBVpS1.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.22%
ROE -19.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.75%
ROA(5y)-32.49%
ROE(3y)-60.9%
ROE(5y)-45.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.86
Quick Ratio 22.86
Altman-Z 20.47
F-ScoreN/A
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)76.01%
Cap/Depr(5y)97.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.65%
EPS Next Y89.9%
EPS Next 2Y26.6%
EPS Next 3Y15.11%
EPS Next 5Y13.12%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-161.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.04%
OCF growth 3YN/A
OCF growth 5YN/A

NOVABRIDGE BIOSCIENCES / NBP FAQ

Can you provide the ChartMill fundamental rating for NOVABRIDGE BIOSCIENCES?

ChartMill assigns a fundamental rating of 3 / 10 to NBP.


Can you provide the valuation status for NOVABRIDGE BIOSCIENCES?

ChartMill assigns a valuation rating of 0 / 10 to NOVABRIDGE BIOSCIENCES (NBP). This can be considered as Overvalued.


How profitable is NOVABRIDGE BIOSCIENCES (NBP) stock?

NOVABRIDGE BIOSCIENCES (NBP) has a profitability rating of 1 / 10.